BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20290325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20291028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260313T133000
DTEND;TZID=Europe/Vienna:20260313T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260302T091708Z
UID:2845-1773408600-1773412200@esmit.eanm.org
SUMMARY:Radiobiological Aspects of PRRT
DESCRIPTION:This webinar will examine the fundamental differences between targeted radionuclide therapy (TRT) and conventional external beam radiotherapy (EBRT)\, integrating physical\, dosimetric\, and radiobiological perspectives relevant to clinical practice. Drawing on the EANM–ESTRO joint session\, the first part will outline how TRT’s systemic administration\, patient-specific pharmacokinetics\, protracted low dose-rate delivery\, and highly heterogeneous intratumoral distribution distinguish it from the controlled\, high dose-rate\, fractionated paradigm of EBRT. Emphasis will be placed on implications for treatment planning\, activity prescription\, imaging-based dosimetry\, and the limitations of directly translating EBRT concepts such as uniform dose coverage and standard fractionation models to TRT. \n\n\n\nThe second part will focus on how absorbed dose\, dose rate\, and spatial heterogeneity influence biological effectiveness and clinical outcomes in TRT. Key topics include sublethal damage repair during continuous irradiation\, challenges in applying conventional radiobiological models\, the impact of microscopic dose non-uniformity (especially for β- versus α-emitting therapies)\, and the relationship between local tumor control and systemic effects\, including immune modulation. The session aims to equip nuclear medicine physicians and medical physicists with a conceptual framework to interpret dosimetry results\, personalize treatments\, and critically evaluate emerging combination strategies as TRT evolves toward a quantitatively driven radiotherapy modality. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nDifferentiate the fundamental physical and clinical characteristics of TRT versus EBRT\, including source geometry\, temporal delivery\, dose-rate profiles\, and implications for treatment planning and prescription.\n\n\n\nExplain how pharmacokinetics and biodistribution govern absorbed dose in TRT\, and why activity administration alone is an insufficient surrogate for delivered dose and therapeutic effect.\n\n\n\nAssess the impact of dose rate and protracted irradiation on radiobiological response\, including sublethal damage repair\, limitations of conventional linear-quadratic modeling\, and consequences for tumor control and normal tissue toxicity.\n\n\n\nRecognize the clinical significance of spatial dose heterogeneity at organ\, tumor\, and cellular scales\, particularly differences between β-emitting and α-emitting radiopharmaceutical therapies.\n\n\n\nInterpret the relationship between dosimetry metrics and clinical outcomes\, including local control\, toxicity\, and potential systemic (immune-mediated) effects.\n\n\n\nApply these concepts to support patient-specific dosimetry\, treatment personalization\, and multidisciplinary decision-making in modern targeted radionuclide therapy practice.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nThis webinar is intended for nuclear medicine physicians and medical physicists involved in targeted radionuclide therapy\, including early-career professionals and practitioners seeking to deepen their understanding of the physical and radiobiological principles underpinning modern TRT practice.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nDavid Sánchez-ArtuñedoSpeaker \n\n\n\n\n\nZachary MorrisSpeaker \n\n\n\n\n\nSamantha TerryModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/radiobiological-aspects-of-prrt/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260319T090000
DTEND;TZID=Europe/Vienna:20260320T123000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260310T121614Z
UID:2807-1773910800-1774009800@esmit.eanm.org
SUMMARY:Dose-Effect Response to Targeted Radionuclide Therapy
DESCRIPTION:UEMS EACCME has granted the accreditation of 10.5 CME credits for this event. \n\n\n\nThis intensive 1\,5-day course bridges the gap between radiobiology\, dosimetry\, and clinical practice in targeted radionuclide therapy. Designed for early-career nuclear medicine physicians and medical physicists\, the programme explores dose-response relationships in the three most commonly used theranostic molecules: somatostatin-ligands for neuroendocrine tumours\, PSMA-inhibitors for prostate cancer\, and radioiodine for thyroid malignancies. \n\n\n\nThrough a balanced faculty of radiobiologists\, dosimetry experts\, and experienced nuclear medicine physicians\, participants will gain practical insights into the biological effects of radiation\, dosimetry calculation methodologies\, and their clinical implementation. The course emphasizes hands-on learning through joint case sessions\, interactive workshops\, and patient-specific treatment planning exercises. \n\n\n\nFormat: Lectures\, case discussions\, interactive workshops\, and panel sessions \n\n\n\n\n\n\n\nRegister nowThe registration is closed. \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nAt the end of the two days\, participants of the course will be able to: \n\n\n\n\nExplain the fundamental radiobiological principles underlying dose-effect relationships in targeted radionuclide therapy and how they differ from external beam radiotherapy and brachytherapy.\n\n\n\nDescribe the complete workflow from imaging acquisition to dose calculation and apply core dosimetry concepts to clinical TRT scenarios.\n\n\n\nIntegrate dosimetry data into clinical decision-making for patient selection\, treatment planning\, and outcome prediction in targeted radionuclide therapy.\n\n\n\nCompare and contrast the clinical applications\, dose-response characteristics\, and dosimetric considerations for somatostatin-ligand therapy (neuroendocrine tumours)\, PSMA-inhibitor therapy (prostate cancer)\, and radioiodine therapy (thyroid disease).\n\n\n\nInterpret key clinical trial outcomes and evidence-based data related to dosimetry-guided TRT across the three major theranostic applications.\n\n\n\nDesign a patient-specific TRT treatment plan incorporating radiobiological principles\, dosimetric calculations\, and clinical considerations for organ protection and tumour targeting.\n\n\n\nIdentify the practical challenges and solutions for implementing dosimetry protocols in routine clinical nuclear medicine practice.\n\n\n\nCritically evaluate when and how personalized dosimetry can optimize therapeutic outcomes and minimize toxicity in individual patients.\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nEarly-career nuclear medicine doctors and medical physicists \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nJulie NonnekensSpeakerNetherlands \n\n\n\n\n\nLars Tore Gyland MikalsenSpeakerNorway \n\n\n\n\n\nFrancesco CiconeSpeakerItaly \n\n\n\n\nFrancesco GiammarilleSpeakerFrance \n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/dose-effect-response-to-targeted-radionuclide-therapy/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260327T133000
DTEND;TZID=Europe/Vienna:20260327T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260320T084326Z
UID:2847-1774618200-1774621800@esmit.eanm.org
SUMMARY:FDG PET/CT in Inflammation and Infection: from Theory to Clinical Practice!
DESCRIPTION:Imaging of infection and inflammation has been part of nuclear medicine since the 1970s. Over the past two decades\, the growing role of FDG PET/CT in diagnosing and monitoring the treatment of a wide variety of infectious and inflammatory diseases has been recognised. As a result\, this technique has recently been adopted in several clinical guidelines. This webinar provides clinical case-based evidence to assist nuclear medicine physicians in recommending\, performing and interpreting FDG PET/CT examinations in patients with infectious and inflammatory disorders. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nThe aim of this live webinar is to describe\, using illustrative clinical cases\, the role of FDG PET/CT in a variety of pathological conditions characterised by infection or inflammation\, with particular emphasis on strengths and limitations of FDG PET/CT.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine Physicians\, Residents\, Technologists\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nAyah NawwarSpeaker \n\n\n\n\n\nDomenico AlbanoSpeaker \n\n\n\n\n\nSøren HessSpeaker \n\n\n\n\n\nLucia LeccisottiModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fdg-pet-ct-in-inflammation-and-infection-from-theory-to-clinical-practice/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260410T133000
DTEND;TZID=Europe/Vienna:20260410T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260410T073326Z
UID:2849-1775827800-1775831400@esmit.eanm.org
SUMMARY:Open your Heart on SPECT and PET Studies: Synergistic Information from the CT
DESCRIPTION:This webinar will cover synergetic information derived from the CT component in SPECT/CT and PET/CT examinations:  the first part we will focus on cardiac calcifications\, offering valuable insights into their detection and clinical relevance especially for myocardial perfusion scans. In the second half\, we will discuss incidental findings in the thorax\, helping clinicians recognize and interpret unexpected observations in SPECT/CT and PET/CT studies.  \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nThis webinar aims to equip attendees with practical knowledge that enhances diagnostic confidence\, facilitates interdisciplinary collaboration\, and improves patient outcomes in hybrid nuclear cardiology examination. Participants will gain a deeper understanding of: \n\n\n\n \n\n\n\n\nCardiac Calcifications with CT: Learn how to identify and assess cardiac calcifications using CT imaging\, recognize their clinical significance\, and understand their implications for cardiovascular disease risk stratification in PET/CT and SPECT/CT myocardial perfusion examinations\n\n\n\nIncidental Findings in the Thorax: Develop the ability to systematically evaluate incidental thoracic findings encountered in SPECT/CT and PET/CT studies\, differentiate between benign and pathological abnormalities\, and enhance decision-making for further clinical assessment.”info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine physicians\, Cardiologists with focus on cardiovascular imaging\, Radiologists\, Technologists\, Residents in Nuclear Medicine.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nManar BadarnahSpeaker \n\n\n\n\n\nChristoph RyffelSpeaker \n\n\n\n\n\nFederico CaobelliModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/open-your-heart-on-spect-and-pet-studies-synergistic-information-from-the-ct/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260416T090000
DTEND;TZID=Europe/Vienna:20260417T123000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260402T074125Z
UID:2823-1776330000-1776429000@esmit.eanm.org
SUMMARY:Nuclear Medicine in FUO/IUO: Why Are Children Different?
DESCRIPTION:This 1\,5-day course focuses on the growing field of integrated imaging in infectious and inflammatory diseases in children\, with an emphasis on hybrid imaging. \n\n\n\nThe panelists will introduce the participants to the specific aspects of paediatric patients in this growing field\, covering the most relevant topics of the clinical scenario and the technical options available in daily practice. \n\n\n\nThe participants will be confronted with frequent and less frequent disease pattern\, with ample opportunity for discussing clinical indications and image interpretation criteria. \n\n\n\nThe continuing interaction between paediatrician\, paediatric radiologist and nuclear medicine physician will show the practical implementation of an integrated approach\, with particular attention to radiation dose reduction and optimisation. \n\n\n\n\n\n\n\nRegistrationThe registration for this course is closed. Please get in touch with us at esmit@eanm.org if you still want to register. \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nAfter the course the participants will be able to: \n\n\n\n\nDescribe the impact of new imaging modalities on the clincial workup of infectious and inflamamtory diseases in children\n\n\n\nIdentify the most relevant indications for hybrid imging in paediatric inflammatory and infectious diseases in children\n\n\n\nDescribe the different protocols for FDG imaging\, selecting the most indiated depending on age group and clinical setting\n\n\n\nDefine the correct workflow for integrated imaging in different clinical situations\, with particular regard to radiation dose optimisation\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nPhysicians\, residents with special interest in paediatrics\, nuclear medicine\, radiology\, nurses and technicians of nuclear medicine or radiology unit. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPietro ZucchettaSpeakerPadova\, Italy \n\n\n\n\n\nSandra TrapaniSpeakerFlorence\, Italy \n\n\n\n\n\nChiara GiraudoSpeakerPadova\, Italy \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/nuclear-medicine-in-fuo-iuo-why-are-children-different/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260508T133000
DTEND;TZID=Europe/Vienna:20260508T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260507T110508Z
UID:2851-1778247000-1778250600@esmit.eanm.org
SUMMARY:Dosimetry in Clinical Trials
DESCRIPTION:Targeted Radionuclide Therapy (TRT) is an expanding field of cancer treatment in which radiopharmaceuticals—comprising a radionuclide linked to a tumour-targeting biological vector—are administered to deliver cytotoxic radiation doses selectively to malignant tissues. The growing development of theragnostic agents\, enabling both imaging and therapy\, has strengthened the rationale for a patient-specific treatment approach. \n\n\n\nIn clinical trials\, dosimetry plays a phase-dependent role: in early-phase studies\, it is essential for establishing safety profiles and dose- toxicity correlations for organs at risk\, while in later phases it contributes to efficacy assessment\, treatment comparison\, and long-term outcome evaluation. This webinar will provide an overview of the regulatory and methodological framework for integrating dosimetry into TRT clinical trials\, with particular emphasis on its role in assessing safety\, efficacy\, and effects. Examples from recent and ongoing trials will be presented to illustrate how dosimetric data can inform trial design\, support treatment personalization\, and ultimately facilitate the transition toward dosimetry-guided therapeutic strategies. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nProvide an overview of the key elements involved in the design of clinical TRT trials.\n\n\n\nExplain the rationale and advantages of implementing dosimetry in TRT clinical trials.\n\n\n\nIdentify key factors for designing dosimetry protocols tailored to the specific radiopharmaceutical and the phase of the clinical trial.”\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nThis webinar is intended for professionals involved in TRT\, mainly nuclear medicine physicians\,  technologists and medical physicists.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nMarta CremonesiSpeaker \n\n\n\n\n\nCaroline StokkeSpeaker \n\n\n\n\n\nAnna SarnelliModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/dosimetry-in-clinical-trials/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260529T133000
DTEND;TZID=Europe/Vienna:20260529T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260520T095929Z
UID:2854-1780061400-1780065000@esmit.eanm.org
SUMMARY:FAP and Stroma Imaging – Current and Future Applications
DESCRIPTION:This presentation provides an overview of fibroblast activation protein (FAP)–directed molecular imaging as a novel approach for tumour staging and theranostic decision-making across multiple malignancies. It introduces the biological role of cancer-associated fibroblasts and stromal remodeling in tumour progression and highlights the rationale for FAP-targeted PET imaging. Clinical evidence from prospective trials and comparative imaging studies is discussed\, demonstrating the diagnostic performance of FAPI PET across tumour entities\, particularly in sarcoma and gastrointestinal cancers\, where high tumour-to-background contrast and strong tracer uptake support improved lesion detection and staging accuracy compared with conventional imaging approaches. \n\n\n\nThe presentation further addresses emerging clinical applications of FAP-directed radioligand therapy (RLT)\, including safety\, dosimetry\, and early response outcomes in patients with advanced solid tumours. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nUnderstand the biological rationale of fibroblast activation protein (FAP) expression in cancer-associated fibroblasts and its relevance as a stromal imaging target across multiple tumour entities.\n\n\n\nRecognize the diagnostic performance and clinical indications of FAPI PET for tumour staging and restaging\, particularly in sarcoma and gastrointestinal malignancies.\n\n\n\nExplain the principles of FAP-directed theranostics and summarize current clinical evidence on safety\, dosimetry\, and response outcomes of FAPI-based radioligand therapy.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear medicine physicians\, radiologists\, medical oncologists\, researchers\, and experts in the field of oncology and inflammation\n\n\n\n\n \n\n\n\nSuggested Reading\n\n\n\n \n\n\n\n1. Hope TA\, Calais J\, Goenka AH\, et al. SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2025 Jan 3;66(1):26-33. doi: 10.2967/jnumed.124.269002. PMID: 39572227; PMCID: PMC11705787. \n\n\n\n2. Hagens MJ\, van Leeuwen PJ\, Wondergem M\, at al. A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers. J Nucl Med. 2024 Jun 3;65(6):888-896. doi: 10.2967/jnumed.123.267260. PMID: 38637140. \n\n\n\n3. Pabst KM\, Fendler WP\, Jochheim LS\, Herrmann K. The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update. Semin Nucl Med. 2025 Sep;55(5):701-709. doi: 10.1053/j.semnuclmed.2025.06.011. Epub 2025 Jul 16. PMID: 40675899. \n\n\n\n4. Pabst KM\, Weber MM\, Laschinsky C\, et al. [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre\, single-arm\, interventional\, phase 2 trial. Lancet Oncol. 2025 Sep;26(9):1204-1214. doi: 10.1016/S1470-2045(25)00299-2. Epub 2025 Aug 4. PMID: 40774265. \n\n\n\n5. Nilsson T\, Rasinski P\, Smedby Ö\, Af Burén S\, et al. Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients. J Nucl Med Technol. 2024 Sep 5;52(3):221-228. doi: 10.2967/jnmt.123.267156. PMID: 38627014. \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nWolfgang FendlerSpeaker \n\n\n\n\n\nAntonios TzorzakakisSpeaker \n\n\n\n\n\nDaniela Oprea-LagerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fap-and-stroma-imaging-current-and-future-applications/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260611T090000
DTEND;TZID=Europe/Vienna:20260612T123000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260526T100413Z
UID:2826-1781168400-1781267400@esmit.eanm.org
SUMMARY:Bringing Therapy Radioisotopes into Clinical Radiopharmacy – Some Regulatory Aspects
DESCRIPTION:“Bringing Therapy Radioisotopes into Clinical Radiopharmacy” is an advanced course designed to bridge the gap between isotope production\, radiopharmaceutical preparation and clinical application. This course focuses on the practical and regulatory hurdles of integrating therapeutic radionuclides into hospital settings. \n\n\n\nDiving into production and purification methods of emerging therapeutic isotopes\, supply chain and matched pairs for theranostics\, we’ll then navigate the regulatory landscape (cGMP\, marketing authorizations\, and clinical trials). Understanding how the radiometals and radiohalogens used in therapy are used for radiopharmaceutical preparation correlates with quality control standards specific to alpha and beta emitters. \n\n\n\nWe will focus on transitioning from a research lab to a clinical radiopharmacy\, revising documentation requirements and facility design for high-energy beta and alpha particles\, and also safety protocols for pharmacists\, radiochemists and technicians. \n\n\n\nThis course provides the blueprint for establishing a modern\, therapy-ready radiopharmacy\, moving beyond diagnostic imaging into the era of personalized molecular radiotherapy. \n\n\n\n\n\n\n\nRegistration is closedPlease get in touch with us at esmit@eanm.org if you still want to register. \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nGeneral knowledge regarding GMP and cGMP for Radiopharmaceuticals principles and guidelines. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nHospital and production radiopharmacists\, and radiochemists involved in clinical trials with radiopharmaceuticals\, hospital radiopharmacy and radiopharmaceutical production. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDana NiculaeSpeakerBucharest\, Romania \n\n\n\n\n\nNeil HartmanSpeakerSwansea Bay\, UK \n\n\n\n\n\nAntero AbrunhosaSpeakerCoimbra\, Portugal \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/bringing-therapy-radioisotopes-into-clinical-radiopharmacy-some-regulatory-aspects/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260619T133000
DTEND;TZID=Europe/Vienna:20260619T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123803Z
UID:2856-1781875800-1781879400@esmit.eanm.org
SUMMARY:Navigating International Guidelines for the Management of Thyroid Cancer
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/navigating-international-guidelines-for-the-management-of-thyroid-cancer/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260630T080000
DTEND;TZID=Europe/Vienna:20280630T170000
DTSTAMP:20260526T120758
CREATED:20260519T123644Z
LAST-MODIFIED:20260520T092320Z
UID:3713-1782806400-1845997200@esmit.eanm.org
SUMMARY:NucMed Essentials - Artifical Intelligence Basics
DESCRIPTION:This course is not yet available\, but coming soon! \n\n\n\n \n\n\n\nArtificial Intelligence (AI) is transforming the landscape of nuclear medicine\, enhancing image analysis\, improving diagnostic accuracy\, optimizing treatment planning\, and streamlining patient management. As AI-driven technologies continue to evolve\, nuclear medicine professionals must develop a strong foundational understanding of AI concepts to effectively integrate these advancements into clinical practice. \n\n\n\nThis online course\, “Essentials of AI for Nuclear Medicine\,” provides a structured introduction to AI\, covering key topics such as machine learning (ML)\, deep learning (DL)\, and cutting-edge AI approaches\, including generative AI. Participants will gain insights into how AI algorithms work\, their applications in nuclear medicine imaging and theranostics\, and the practical challenges associated with implementing AI in a clinical setting. \n\n\n\nThe course introduces fundamental AI principles\, including supervised and unsupervised learning\, neural networks\, convolutional neural networks (CNNs)\, transformer-based architectures\, and generative models such as GANs and diffusion models. Special emphasis will be placed on AI’s role in PET and SPECT imaging\, lesion detection\, segmentation\, dosimetry\, and radiopharmaceutical therapy (RPT). \n\n\n\nDesigned for nuclear medicine physicians\, medical physicists\, technologists\, and researchers\, this course bridges the gap between AI and clinical applications\, empowering participants to critically understand AI tools and leverage AI-driven technologies in their daily practice. Through six hours of online lectures\, attendees will gain the knowledge and confidence to navigate the evolving intersection of AI and nuclear medicine effectively. Medicine\,” is designed to provide nuclear medicine professionals with a fundamental understanding of AI concepts\, including machine learning (ML)\, deep learning (DL)\, and emerging AI technologies such as generative AI. The course will bridge the gap between AI and clinical practice\, empowering participants to integrate AI solutions into their workflow. \n\n\n\n \n\n\n\n\n\n\n\nRegistration will be open soonThe link to register will be available shortly. Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\n\nTo understand the fundamental principles of Artificial Intelligence (AI)\n\n\n\nTo learn about key AI architectures\n\n\n\nTo stay informed about the applications of AI in nuclear medicine\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\nNuclear medicine physicians\, medical physicits\, technologies and researchers\, who have no AI experience \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nLászló PappSpeaker \n\n\n\nMathieu HattDesignation \n\n\n\n\n\nDimitris VisvikisDesignation \n\n\n\n\n\nKuangyu ShiDesignation
URL:https://esmit.eanm.org/event/nucmed-essentials-artifical-intelligence-basics/
CATEGORIES:NucMed Essentials
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260703T133000
DTEND;TZID=Europe/Vienna:20260703T143000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091236Z
UID:2859-1783085400-1783089000@esmit.eanm.org
SUMMARY:Auger Electron Emitters – Why Consider this Therapeutic Option?
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/auger-electron-emitters-why-consider-this-therapeutic-option/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260709T090000
DTEND;TZID=Europe/Vienna:20260710T123000
DTSTAMP:20260526T120758
CREATED:20251004T070000Z
LAST-MODIFIED:20260521T101051Z
UID:2829-1783587600-1783686600@esmit.eanm.org
SUMMARY:PET in Multiple Myeloma: Evidences\, Applications and Perspectives
DESCRIPTION:This onsite course on FDG PET/CT in multiple myeloma is a focused\, practice-oriented training programme designed to enhance expertise in metabolic imaging of plasma cell disorders. The course integrates concise lectures\, case discussions\, and supervised workstation-based interpretation to provide immersive\, hands-on learning.The programme includes a review of the pathophysiology of multiple myeloma and the biological mechanisms underlying FDG uptake. Faculty outline current evidence and guideline recommendations for PET/CT in staging\, treatment response assessment\, and leasions detection\, as well as MRI applications. Participants learn optimal patient preparation\, acquisition protocols\, and technical considerations that influence image quality and quantitative analysis\, including harmonization strategies.  A central component of the course is interactive case interpretation across diverse disease settings. Attendees analyze studies from patients with smoldering myeloma\, newly diagnosed active disease\, plasmacytomas. Special attention is given to identifying focal lesions\, diffuse bone marrow infiltration\, extramedullary and paramedullary disease\, and to distinguishing viable tumour from post-treatment changes. Structured reporting workshops guide participants in applying standardized interpretation criteria and incorporating metabolic findings into clinically meaningful reports. Correlation with laboratory markers\, bone marrow biopsy results\, and other imaging modalities reinforces integrated decision-making. \n\n\n\nBy the end of the course\, participants gain practical confidence in accurate interpretation\, standardized reporting\, and clinical application of FDG PET/CT across the full spectrum of multiple myeloma disease scenarios.  \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo review current clinical indications and guidelines for FDG PET/CT in plasma cell disorders\, including staging\, response assessment\, minimal residual disease evaluation\, and relapse detection.\n\n\n\n\n\nTo develop practical skills in image interpretation across different disease settings\, including smoldering myeloma\, newly diagnosed active disease\, solitary plasmacytoma\, treated disease\, and relapsed or refractory myeloma.\n\n\n\n\n\nTo recognize and characterize patterns of disease involvement\, such as focal lesions\, diffuse bone marrow infiltration\, extramedullary disease\, and paramedullary extension.\n\n\n\n\n\nTo identify common pitfalls and artifacts in PET/CT imaging and distinguish active disease from post-therapeutic changes\, fractures\, inflammation\, or infection.\n\n\n\n\n\nTo apply standardized interpretation and reporting criteria\, incorporating semi-quantitative parameters (e.g.\, SUV measurements) into structured\, clinically meaningful reports.\n\n\n\n\n\nTo integrate PET/CT findings with clinical\, laboratory\, and histopathological data to support multidisciplinary decision-making.\n\n\n\n\n\nTo enhance confidence in independent reporting and clinical application of FDG PET/CT in the management of patients with multiple myeloma.\n\n\n\n\n \n\n\n\nTarget Audience\n\n\n\nNuclear Medicine Physicians \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDavideBezziSpeakerCesena/Forlì\, Italy \n\n\n\n\n\nChristos SachpekidisSpeakerAlexandroupolis\, Greece \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/pet-in-multiple-myeloma-evidences-applications-and-perspectives/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260821T120000
DTEND;TZID=Europe/Vienna:20260821T130000
DTSTAMP:20260526T120759
CREATED:20260519T121442Z
LAST-MODIFIED:20260519T122534Z
UID:3700-1787313600-1787317200@esmit.eanm.org
SUMMARY:JSNM/ESMIT - SPECT and PET in the Contemporary Assessment of Cardiac Amyloidosis
DESCRIPTION:This joint webinar will provide a focused and clinically relevant overview of the role of nuclear medicine in the evaluation of cardiac amyloidosis. The first lecture will address the established value of bone-avid tracer SPECT/CT for non-invasive diagnosis\, including acquisition strategy\, image interpretation\, common pitfalls and integration with the broader diagnostic work-up. The second lecture will explore the evolving contribution of PET\, highlighting tracer biology\, quantitative opportunities\, disease characterization and the potential role of PET for earlier detection and treatment monitoring. Together\, the two talks will offer attendees a practical and up-to-date framework for understanding how SPECT and PET can complement each other along the diagnostic and management pathway of patients with suspected or confirmed cardiac amyloidosis. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nReview the current role of bone-avid tracer SPECT/CT in the non-invasive diagnosis of cardiac amyloidosis\, including key interpretation criteria and diagnostic pitfalls.\n\n\n\nUnderstand the emerging value of PET in cardiac amyloidosis\, with emphasis on tracer selection\, disease characterization\, quantification and future clinical applications.\n\n\n\nIntegrate nuclear medicine findings into a multidisciplinary diagnostic pathway\, improving confidence in image interpretation and supporting patient-centered clinical decision-making.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\nNuclear Medicine physicians\, Cardiologists with a focus on cardiovascular imaging\, Radiologists\, Internists involved in amyloidosis care\, Technologists\, Fellows and Residents. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nTakashi KudoSpeaker \n\n\n\n\n\nPierre-Yves MarieSpeaker \n\n\n\n\n\nFederico CaobelliModerator
URL:https://esmit.eanm.org/event/jsnm-esmit-spect-and-pet-in-the-contemporary-assessment-of-cardiac-amyloidosis/
CATEGORIES:Live Webinars
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260918T133000
DTEND;TZID=Europe/Vienna:20260918T143000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091347Z
UID:2861-1789738200-1789741800@esmit.eanm.org
SUMMARY:Trustworthy AI and Human Oversight
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/trustworthy-ai-and-human-oversight/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260924T090000
DTEND;TZID=Europe/Vienna:20260925T123000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123139Z
UID:2831-1790240400-1790339400@esmit.eanm.org
SUMMARY:Prostate Cancer Theranostics
DESCRIPTION:More information will come soon. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeThe programme will come soon. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/prostate-cancer-theranostics-2/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261106T133000
DTEND;TZID=Europe/Vienna:20261106T143000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091508Z
UID:2863-1793971800-1793975400@esmit.eanm.org
SUMMARY:With a Little Help of Artificial Intelligence for the Sake of Radiation Protection
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/with-a-little-help-of-artificial-intelligence-for-the-sake-of-radiation-protection/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261112T090000
DTEND;TZID=Europe/Vienna:20261113T123000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20250930T145535Z
UID:2833-1794474000-1794573000@esmit.eanm.org
SUMMARY:Biomarker Assessment for an Early Biological Diagnosis of Alzheimer's Disease
DESCRIPTION:More information will come soon. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeThe programme will come soon. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeCancellation Policy\n\nCourse Fee               FREE \n\n\n\nCourse includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nCourse does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/biomarker-assessment-for-an-early-biological-diagnosis-of-alzheimers-disease/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261127T133000
DTEND;TZID=Europe/Vienna:20261127T143000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123905Z
UID:2865-1795786200-1795789800@esmit.eanm.org
SUMMARY:Ring Geometry SPECT/CT System
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/ring-geometry-spect-ct-system/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261203T090000
DTEND;TZID=Europe/Vienna:20261204T123000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20251111T123336Z
UID:2835-1796288400-1796387400@esmit.eanm.org
SUMMARY:Focus on Benign Thyroid Disease: From Thyroid Nodule to Hyperthyroidism and Immune Disease
DESCRIPTION:More information will come soon. \n\n\n\n\n\n\n\nRegister nowRegistration is now open\, save yourself a seat! Register now\n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\nMore info will come soon. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nProgrammeThe programme will come soon. View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nNEW Department Package: If you send 5 participants from your department\, you will get an additional 6th seat for free for this course. Please get in touch with the ESMIT office if this is of interest to you. \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card. Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/focus-on-benign-thyroid-disease-from-thyroid-nodule-to-hyperthyroidism-and-immune-disease-2/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261211T133000
DTEND;TZID=Europe/Vienna:20261211T143000
DTSTAMP:20260526T120759
CREATED:20251004T070000Z
LAST-MODIFIED:20251001T091729Z
UID:2867-1796995800-1796999400@esmit.eanm.org
SUMMARY:Tips and Tricks on Imaging with New CZT SPECT Systems
DESCRIPTION:More info will come soon \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nMore info will come soon\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerSpeaker \n\n\n\n\n\nSpeakerModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/tips-and-tricks-on-imaging-with-new-czt-spect-systems/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20261231T000000
DTEND;TZID=Europe/Vienna:20261231T235900
DTSTAMP:20260526T120759
CREATED:20220901T101846Z
LAST-MODIFIED:20251016T123526Z
UID:1315-1798675200-1798761540@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics – Part 1: Research Design
DESCRIPTION:UEMS EACCME has granted the accreditation of 4 CME credits for this event. \n\n\n\nThis online course is part of a long line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.  \n\n\n\nThese first two modules will represent part one of the course.  \n\n\n\nModule 1 will focus on the entire path from preclinical development to clinical translation of an imaging compound\, including the preclinical studies needed for the selection of a new candidate for clinical translation\, an overview of EU legislation on radiopharmaceuticals for diagnosis and therapy\, and the assessment of quality data and non-clinical data (pharmacology\, dosimetry and toxicology) for the IMP dossier.  \n\n\n\nModule 2 will be focused on the design of a proper trial. It will cover: the definition of objectives\, aims\, endpoints\, population\, statistical methods and examples of trial design schemes\, as well as dosimetry as far as healthy organs and in case of therapy tumour-absorbed dose. It will have a special focus on phase 0\, phase 1-2 trial\, early clinical phase 0-1-2 and investigator-driven clinical trial. \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n\n\nLearning Objectives:\n\n\n\nLearn about: \n\n\n\n\nPreclinical development and clinical translation of radiopharmaceuticals \n\n\n\nThe legislation on radiopharmaceuticals with a specific focus on the European scenario \n\n\n\nRequirements of IMPD for radiopharmaceuticals for imaging agents and theranostic/therapeutic molecules Interpretation of preclinical data to properly design and plan the clinical trial \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals design \n\n\n\nPhase 0\, phase 1 and phase 2 clinical trials with radiopharmaceuticals conductance \n\n\n\nGMP\, GLP and GCP principles \n\n\n\nImportance of radioprotection and dosimetric estimates in early phase clinical trials\n\n\n\n\n\n\n\n\n\n\n\n\nTarget Audience:\n\n\n\n\nResearchers\, scientists\, nurses\, pharmacologists\, radiopharmacists\, residents and specialists in Nuclear Medicine/Oncology/Radiology who want to understand how clinical trials with radiopharmaceuticals in the early phase are unique and how the corresponding documents and trial design should be appropriately planned.\n\n\n\n\n\n\n\n\n\n\nProgrammeClick to see the full event programme.  View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nPaola Anna ErbaUniversità degli Studi di Milano-Bicocca\, Italy \n\n\n\n\n\nSona BalogovaComenius University\, Bratislava\, Slovakia \n\n\n\n\n\nElisabeth von GuggenbergMedical University Innsbruck\, Austria \n\n\n\n\n\n\n\nMartina SolliniVita-Salute San Raffaele University\, Milan\, Italy \n\n\n\n\n\nLuigi AlojUniversity of Cambridge\, United Kingdom \n\n\n\n\n\nMeltem OcakIstanbul University\, Turkey \n\n\n\n\n\n\n\nPeter LavermanRadboud Universiteit Nijmegen\, The Netherlands \n\n\n\n\n\nJane SosabowskiQueen Mary\, University of London\, United Kingdom \n\n\n\n\n\nPetra KolencUniversity Medical Centre Ljubljana\, Slovenia \n\n\n\n\n\n\n\nClemens DecristoforoMedical University Innsbruck\, Austria \n\n\n\n\n\nPiotr GarnuszekPOLATOM\, Warsaw\, Poland \n\n\n\n\n\nRenata MikolajczakPOLATOM\, Warsaw\, Poland \n\n\n\n\n\n\n\nTheodosia MainaNCSR Demokritos\, Athens\, Greece \n\n\n\n\n\nMark KonijnenbergErasmus MC\, Rotterdam\, The Netherlands \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\nRegistration Fee\n\nCourse Fee              Free \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fundamentals-of-research-in-imaging-and-theranostics-part-1-research-design/
LOCATION:Online
CATEGORIES:Research Methods,Self-paced Online Course
END:VEVENT
END:VCALENDAR